Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Cyclerion Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4.51
2.3
3.94
0.3
0
2
2.07
Research and development
87.7
95.1
56.4
37.6
5.98
1.52
0.29
0.96
General and administrative
27.5
34.4
28.8
20.6
12.9
8.13
5.34
6.09
Operating expenses
115
130
83.6
59.1
18.8
13
5.63
7.05
Operating income
-115
-125
-81.3
-55.2
-18.5
-13
-3.63
-4.97
Other non-operating income
0.59
-0.02
0.29
0.36
0.57
1.45
Pre-tax income
-115
-122
-122
-51.6
-44.1
-5.26
-3.06
-3.53
Income tax
0
0
0
0
0
0
0
0
Net income
-115
-123
-77.8
-51.6
-44.1
-5.26
-3.06
-3.53
EBITDA
-114
-122
-79
-54.7
-18.5
-13
EPS, basic
-84.53
-90.16
-51.40
-26.50
-20.28
-2.25
-1.21
-1.11
EPS, diluted
-84.53
-90.16
-51.40
-26.50
-20.28
-2.25
-1.21
-1.11
Shares, basic (weighted)
0
1.36
1.51
1.95
2.17
2.34
2.52
3.18
Shares, diluted (weighted)
0
1.36
1.51
1.95
2.17
2.34
2.52
3.18
Balance sheet
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0
94.9
54.4
54
13.4
7.57
3.23
3.24
Receivables
0
0.1
0.1
0
0.56
1
Other current assets
0.01
2.86
3.16
0.47
0.54
0.01
0.02
0.01
Total current assets
0.88
101
58.5
55.5
14.8
8.02
4.23
4.64
Property, plant and equipment
6.5
11.6
6.87
0.07
0
0
0
0
Lease right-of-use assets
68.1
43.4
1.4
1.22
0
Other non-current assets
0.03
0.54
2.77
2.41
2.04
0
Total assets
7.4
186
115
59.3
18.1
13.4
9.58
9.99
Accounts payable
2.78
3.23
1.15
1.83
2.97
1.2
0.39
0.51
Accrued liabilities
0.03
0.01
Short-term debt
3.5
3.5
3.5
Total current liabilities
17.8
18.2
17
11.1
7.63
2.09
0.73
0.9
Lease liabilities
70.5
38.9
0
Total liabilities
17.8
88.7
55.9
11.1
7.63
2.09
0.73
0.9
Paid-in capital
183
223
263
270
276
276
280
Retained earnings
-85.6
-163
-215
-259
-264
-267
-271
Other comprehensive income
-0.02
-0.03
-0.02
-0.02
-0.01
0
Shareholders' equity
-10.4
97.7
59.5
48.2
10.5
11.3
8.85
9.09
Total equity
-10.4
97.7
59.5
48.2
10.5
11.3
8.85
9.09
Total liabilities and equity
7.4
186
115
59.3
18.1
13.4
9.58
9.99
Shares outstanding
0
1.37
1.7
2.16
2.18
2.47
2.55
3.82
Cash flow statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-115
-123
-77.8
-51.6
-44.1
-5.26
-3.06
-3.53
Depreciation and amortization
1.53
2.7
2.3
0.47
0.07
0
Stock-based compensation
12.4
19.6
15
9.61
6.25
1.07
0.63
0.44
Change in receivables
0
-0.1
0
0.1
-0.56
-0.44
Cash from operations
-97.5
-102
-72.5
-36.5
-40.6
-21.2
-4.33
-3.31
Capital expenditures
-3.44
-6.89
-1.52
-0.01
0
Cash from investing
-3.44
-6.72
0.02
1.46
0
10.4
0
Stock issued
0
5
0
1.38
Cash from financing
101
212
28.1
30.8
0.03
5.02
0
3.32
Exchange rate effect
-0.02
-0.01
0
0
0.01
-0.01
0
Net change in cash
103
-44.4
-4.27
-40.6
-5.81
-4.34
0.01
Free cash flow
-101
-109
-74
-36.5
-40.6
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.36 on October 14, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-359.2%
Operating income / revenue.
Net margin
-353.0%
Net income / revenue.
Operating cash flow margin
-234.3%
Cash from operations / revenue.
Return on equity (ROE)
-131.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-96.8%
Net income / average total assets.
Return on invested capital (ROIC)
-145.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
84.1%
Research and development expense / revenue.
Stock-based pay / revenue
16.9%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
3.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
91.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-2.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
2.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-4.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-31.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
4.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-18.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-38.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
26.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
13.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
16.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.82x
Current assets / current liabilities.
Quick ratio
0.75x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.75x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.45
Revenue / diluted weighted shares.
Operating cash flow per share
-$1.05
Cash from operations / diluted weighted shares.
Book value per share
$1.20
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
8.28x
Market cap / revenue.
P/B
3.09x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.09x
Market cap / tangible book value, when positive.
EV/Sales
7.55x
Enterprise value / revenue.
Earnings yield
-42.6%
Net income / market cap (the inverse of P/E).
What was Cyclerion Therapeutics, Inc.'s revenue in fiscal 2025?
Cyclerion Therapeutics, Inc. reported revenue of $2.1M for fiscal 2025, 3.7% higher than the year before.
Was Cyclerion Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $3.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.